Mephedrone: still available and twice the price

  title={Mephedrone: still available and twice the price},
  author={Adam R Winstock and Luke Mitcheson and John Marsden},
  journal={The Lancet},
Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity
  • D. Wood, P. Dargan
  • Biology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2012
A Preference for Mephedrone: Drug Markets, Drugs of Choice, and the Emerging “Legal High” Scene
Respondents’ preferences were guided by pharmacological properties that helped them conceal the effects of mephedrone in public and semi-public spaces, and were not deterred by the (impending) change from legal to illicit drug.
Clinical Pharmacology of the Synthetic Cathinone Mephedrone.
This chapter reviews the available published data on patterns of mephedrone use, its acute and chronic effects, and its pharmacokinetic properties and concludes that more human research is needed to elucidate the safety, toxicity, and addiction potential of me phedrone and related NPS.
Mephedrone: when science and policy fell out
Mephedrone is a stimulant drug of abuse whose public profile rose dramatically in 2009. At that time, it was designated as ‘legal high’ and was predominantly sold over the Internet for as little as
Simultaneous use of mephedrone and alcohol: A qualitative study of users' experiences
The results suggest a three-tier classification system that describes users’ experiences with simultaneous use of mephedrone and alcohol, and have the potential for informing socioepidemiological surveys as well as peer interventions to reduce harm associated with simultaneous drug use.
Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland
Mephedrone (4-methylmethcathinone) is a synthetic ‘amphetamine-type stimulant’ (ATS) derived from the Khat plant and collectively known as ‘M-Cats’. Research has indicated the presence of strong
Neurotoxicity Induced by Mephedrone: An up-to-date Review
This review examines the emerging scientific literature on the possible mephedrone-induced neurotoxicity, yet not well defined due to the limited number of experimental studies, mainly carried on animal models to establish an appropriate treatment for substance abuse and eventual consequences for public health.
The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample
The NBOMe drugs have emerged recently, are frequently bought using the internet and have similar effects to other hallucinogenic drugs; however, they may pose larger risks, due to the limited knowledge about them, their relatively low price and availability via the internet.


Mephedrone, new kid for the chop?
Mephedrone appears to be used primarily intranasally and to have comparable abuse potential to cocaine, with more than half those who use both reporting that mephedrone gives a better quality high.
Depression and Alzheimer's disease: Symptom or comorbidity?
Findings indicate that depressive symptoms, if specifically treated, tend to reduce caregiver stress and improve well-being in patients with Alzheimer's disease, and that SSRI intake seems to be effective for depression, decreasing it and improving quality of life for both patients and caregivers.
The effect of different diagnostic criteria on the prevalence of dementia.
The commonly used criteria for diagnosis can differ by a factor of 10 in the number of subjects classified as having dementia, having serious implications for research and treatment, as well as for the right of many older persons to drive, make a will, and handle financial affairs.
The Costs of Caring: Impact of Dementia on Family Caregivers
The physical and psychological effects of providing care to a family member with a dementing illness are examined, and several approaches to caregiver intervention designed to reduce the negative impact of this challenging role are discussed.
Is it time to retire the term "dementia"?
  • P. Sachdev
  • Psychology, Medicine
    The Journal of neuropsychiatry and clinical neurosciences
  • 2000
Received August 3, 1999; November 17, 1999; accepted January 17, 2000. From the School of Psychiatry, University of New South Wales, and Neuropsychiatric Institute, The Prince of Wales Hospital,
What should be done about mephedrone?
The authors should focus on crafting the most effective public health response to climate change, and not worry about how to respond to natural disasters.